Rongchang Biopharma Launches a Full-Scale Offensive

Rongchang Biopharma is accelerating the delivery of its ambitious blueprint. On August 22, the company released its 2025 interim report with standout results:

• Total revenue reached RMB 1.09 billion, up 48% year over year;
• Composite gross margin rose 5.8 percentage points to 84%;
• Selling expense ratio fell 4.6 percentage points to 47.9%;
• Net loss narrowed by 42.4% to RMB 450 million, showing a clear trend of loss reduction.

The continued improvement across multiple financial metrics not only validates the efficient conversion of the company’s in-house R&D prowess and commercialization capabilities, but also highlights a marked acceleration in operating tempo. Previously, Rongchang Biopharma projected a substantial narrowing of losses in 2025, break-even in 2026, and entry into profitability in 2027. Judging from current momentum, the pathway to those goals is now clearly in sight—and may even be achieved ahead of schedule. With performance on a steady upswing, the outlook is increasingly promising.

Behind these changes lie major breakthroughs in commercialization and internationalization: (1) the already marketed products Telitacicept and Disitamab Vedotin continue to expand into new indications and deepen market penetration, driving strong sales growth; and (2) the pace of overseas BD has accelerated significantly, with core assets in oncology, autoimmune diseases, and ophthalmology successively out-licensed abroad, forming a new international landscape. With increasingly mature R&D strength and commercialization capability, Rongchang Biopharma is steadily unlocking its value and writing its own footnote in China’s innovative-drug upgrade journey.

Business Fundamentals Continue to Improve

Rongchang Biopharma’s fundamentals are optimizing at an impressive pace. In 2024, the company achieved nearly RMB 1.7 billion in product sales revenue, a visibly faster growth rate than in prior years, mainly thanks to its “twin-star” products—Telitacicept and Disitamab Vedotin—gradually opening up the autoimmune and oncology markets.

Entering 2025, the commercial value of the two core products has been further released, lifting Rongchang Biopharma to a new height. Over the past six months, total revenue exceeded RMB 1.0 billion, up 48% year over year. Full-year revenue is poised to break the RMB 2.0 billion mark, sustaining a high-growth trajectory.

Commercial scale-up has not only rapidly increased revenue but also demonstrated robust product profitability and cost control. By continuously expanding commercial capacity and deepening lean manufacturing, the company’s composite gross margin climbed to 84%, achieving coordinated growth in “volume, price, and quality.” Notably, high revenue growth did not come at the expense of a higher selling expense ratio; in fact, this metric continued to decline. This indicates Rongchang Biopharma has smoothly moved past the market-introductory phase of innovative drug launches and found a balance between rapid market expansion and effective cost control—entering a brand-driven virtuous growth track.

At a deeper level, this shift reflects growing recognition among physicians and patients of the clinical value of Telitacicept and Disitamab Vedotin, gradually establishing a dual-engine growth model driven by brand effects and clinical reputation, and reducing reliance on traditional, headcount-driven sales expansion. Meanwhile, high commercial growth has brought sustained cash flow. Coupled with funds previously raised via Hong Kong share placement and subsequent upfront payments from overseas out-licensing, multiple funding sources are coalescing into strong financial support, providing a solid foundation for continued development.

On R&D investment, the company has optimized by focusing on core pipelines and improving resource allocation efficiency. The combined effect of improved financial metrics is significant—losses have fallen sharply year over year, with net loss attributable to shareholders narrowing to RMB 450 million, a notable improvement versus the same period in 2024. All signs suggest the company is not far from break-even.

Opening a Comprehensive “Go-Global” Front

While commercialization surges at home, Rongchang Biopharma is also fighting on a second front—steadily advancing its international strategy and moving from “single-point breakthroughs” to a new stage of “comprehensive going-global.” This has brought not only considerable cash inflows, but more importantly, proof of the international competitiveness of its R&D outputs.

To date, core products across the company’s three business segments—oncology, autoimmune, and ophthalmology—have been out-licensed overseas via BD, validating the international competitiveness of its pipeline and reinforcing the value connotation of “China Innovation” in global markets. The overseas pace has clearly quickened this year, with two major BD deals closed in the past two months, signaling a more proactive embrace of the era of globalizing China’s innovative drugs.

The changes extend beyond deal frequency; the logic behind partner selection reflects a maturing go-global strategy. Take the out-licensing of RC28: Rongchang teamed up with Santen, Asia’s largest ophthalmic pharmaceutical company with over a century of history—an astute strategic choice. For RC28’s commercialization, this brings both deep ophthalmology expertise and a powerful marketing network. For Santen, whose China portfolio has concentrated on ocular-surface conditions such as glaucoma and dry eye, in-licensing RC28 helps extend its footprint into retinal diseases, filling portfolio gaps; it is highly likely to devote substantial resources to RC28.

The logic of value maximization also runs through the Telitacicept deal. Although the partner Vor Biopharma is not an industry giant, Rongchang obtained a 23% equity stake to become its largest shareholder, enabling deep participation in Telitacicept’s global development—an important embodiment of the upgraded role of Chinese innovators within the global industry value chain. Rongchang’s practice shows that through deep, collaborative BD out-licensing, Chinese pharma is gradually transforming from a simple “product exporter” into a key participant in global innovation and market development, gaining a stronger voice on the international stage.

Deepening Core Assets and Building a Multi-Layered Pipeline

Whether in commercialization or new-indication development, the core products Telitacicept and Disitamab Vedotin carry high market expectations and are poised to become blockbuster therapies in autoimmune diseases and HER2-expressing solid tumors, forming a solid base for the company.

For biopharma companies, launching a new drug is only the starting point; subsequent deep development is key. Telitacicept is drawing ever closer to blockbuster status. It plans to submit marketing applications in the second half of this year for two indications—IgA nephropathy and Sj?gren’s syndrome—both with large patient populations and significant unmet needs. Especially in Sj?gren’s syndrome, with a prevalence in China of 0.3%–0.7%, no biologic has yet been approved globally. Telitacicept ranks among the front-runners; its domestic phase III study met the primary endpoint and the product is expected to become the world’s first targeted biologic for this disease. Beyond opening new commercial opportunities, this will also extend the product life cycle and underpin long-term value creation.

The frontline-therapy potential of Disitamab Vedotin in gastric cancer (GC), urothelial carcinoma (UC), and breast cancer (BC) is also steadily emerging. The phase III trial of combination therapy in first-line UC produced positive results and a new drug application has been filed; the phase III trial of combination therapy in first-line HER2-low gastric cancer has started and begun enrolling; and the BLA for monotherapy in second-line HER2-low breast cancer was accepted in the second quarter. These advances lay a solid foundation for broader application of Disitamab Vedotin in oncology.

Rongchang Biopharma is not reliant on just one or two successes. Through three technology platforms—antibodies & fusion proteins, antibody-drug conjugates (ADC), and bispecific antibodies—the company has built a layered, forward-looking pipeline. In oncology, several rising stars are emerging, notably RC148 in the PD-(L)1/VEGF arena. RC148 is a differentially designed PD-1/VEGF bispecific that uses a nanobody on the anti-VEGF arm, improving tissue penetration and tumor infiltration. The program is advancing quickly and recently received Breakthrough Therapy Designation from China’s CDE, providing an initial validation of its clinical value. In addition, the FDA has cleared a phase II trial in the United States across multiple solid tumors, paving the way for accelerated international development and subsequent phase III studies.

Beyond that, the company is quietly advancing next-generation platform assets such as RC278 and RC288, underscoring deep innovative capabilities. RC278 is a novel ADC with an undisclosed target; a China phase I/II trial in solid tumors has begun. RC288 is a bispecific ADC employing new-generation linker and payload technologies and is currently in the IND-preparation stage.

The strategy is clear: expand indications of marketed products to strengthen commercial growth engines; and build a differentiated, forward-leaning pipeline around cutting-edge technologies to power long-term, sustainable development. This balance between near-term and mid-to-long-term interests enables a virtuous “R&D → commercialization → re-investment in R&D” cycle, boosting overall resilience while expanding the company’s value-creation potential.

Conclusion

With successful launches and indication expansions, Rongchang Biopharma has honed more efficient practices for developing innovative products. Through sequential overseas BD across its three pillars—oncology, autoimmune, and ophthalmology—the company is pursuing a “three-arrows” strategy to globalize its core assets. As revenue rises, profits improve, and expenses optimize, Rongchang is steadily approaching the profitability inflection point. Overall, the company is entering a new stage of accelerated value realization with a “full-line assault.”

Looking ahead, key challenges remain: how to further unlock other promising assets in the pipeline; how to maintain technological leadership and clinical differentiation amid intensifying global competition; and how to balance innovation with commercialization on the path to sustained profitability. If these hurdles are successfully overcome, Rongchang Biopharma could evolve from an outstanding biopharma company into a globally influential leader.